Survival curves showed that in primary and recurrent gliomas, the survival time of patients with low levels of EMP3 was superior to that of patients with high levels of EMP3, with p < 0.001 (Figure 3a,b). This evidence concerns the gene EMP3 and central nervous system cancer.